Frequency and distribution of HPV genotypes in 800 genital samples of Ecuadorian men and women from the city of Guayaquil by Muentes, Gustavo David García et al.
Rev Inst Med Trop São Paulo. 2019;61:e41 Page 1 of 5
BRIEF COMMUNICATION
http://doi.org/10.1590/S1678-9946201961041
This is an open-access article distributed under the 
terms of the Creative Commons Attribution License.
1Sociedad de Lucha Contra el Cáncer, 
Guayaquil, Ecuador
2Universidad Católica de Santiago 
de Guayaquil, Facultad de 
Medicina, Guayaquil, Ecuador
3Centro Dertamológico Ollague, Unidad 
Dermatológica Ollague, Guayaquil, Ecuador
4Universidad de Especialidades Espíritu 
Santo, Samborondón, Ecuador
Correspondence to: Juan Carlos Ruiz 
Cabezas 
Sociedad de Lucha Contra el Cáncer, 
Avenida Pedro Menéndez Gilbert y 
Atahualpa Chávez, 5225-3623, Provincia 
del Guayas, Guayaquil, Ecuador 
Tel: +59 34 371-8700 ext 2147,  
+59 34 371-8300 ext 2143
E-mail: jruiz@solca.med.ec 
 jcruizc@hotmail.com
Received: 15 January 2019
Accepted: 16 July 2019
Frequency and distribution of HPV genotypes in 
800 genital samples of Ecuadorian men and women 
from the city of Guayaquil
Gustavo David García Muentes1,2, Marcia Adelaida Mendoza García1, 
Ramiro Israel Burgos Galárraga1, Kleber Ollague3, Cynthia Vargas Wachter2, 
Juan Carlos Ruiz Cabezas 1,4
ABSTRACT
Even though there are data published on HPV epidemiology in Ecuador, the distribution of 
genotypes in Guayaquil, the largest city in the country, has not been previously determined in 
a study including including both, men and women. The present study aimed to determine the 
distribution of 37 HPV genotypes in genital samples from Ecuadorian men and women living 
in the city of Guayaquil. Genital samples included in daily diagnostic routine were analyzed 
by the 37 HPV GenoArray Diagnostic Kit (Hybribio® Ltd., Sheung Wan, Hong Kong). The 
relative frequency of detectable genotypes was determined. HPV relative frequency according 
to sample characteristics, including sex and age groups, was compared using c2 test. From 
the 800 samples (400 men and 400 women), 411 (51.38%) were positive for HPV DNA. The 
obtained frequency was higher among samples from men (253/400 or 63.25%) in comparison 
to samples from women (158/400 or 39.50%), with a p value <0.05. Samples from men 
showed a higher frequency of HPV genotypes 6, 16, 18 and 11, while among samples from 
women genotypes 39, 16, 6 and 58 were the most frequent. Considering male and female 
samples together, genotypes 6, 16, 39 and 11 presented the highest frequencies. HPV DNA 
was detected in half of the studied samples, with a higher frequency among samples from 
men. Genotype 39 was the most frequent among women, and ranked third when samples 
from men and women are analyzed together. 
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INTRODUCTION 
Human Papillomavirus (HPV) genital infection, constitutes the most common 
sexually transmitted disease worldwide1. HPV is considered a highly contagious 
pathogen, transmitted by sexual contact, by contact with the skin or through 
inanimate objects2-6. According to the International Agency for Research in Cancer 
(IARC) and the World Health Organization (WHO), 12 HPV genotypes, namely 
16, 18, 31, 33, 35, 39, 45 51, 52, 56, 58 and 59, are considered high risk genoypes 
and belong to the group I of human biologic carcinogens. HPV 68 is classified as 
probably carcinogenic and genotypes 26, 30, 34, 53, 66, 67, 69, 70, 73, 82 and 85 
are classified as possibly carcinogenic; these genotypes correspond to groups 2A 
and 2B, respectively7,8. In previous studies on HPV epidemiology in Ecuador, many 
authors have identified a number of genotypes that were not HPV16 and HPV189-13. 
The bivalent vaccine (HPV genotypes 16 and 18), which offers cross protection 
for some HPV genotypes of the same group as HPV16 (HPV31, HPV33, HPV35, 
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HPV52, HPV58) and HPV18 (HPV39, HPV45, HPV59, 
HPV68), is funded by the government14-16. As the frequency 
of genotypes other than HPV16 and 18 is still not clear in 
Ecuador, the present study aimed to determine the relative 
frequency and distribution of HPV genotypes in 800 genital 
samples (400 obtained from men and 400 obtained from 
women), included in the daily diagnostic routine of the 
Instituto Oncológico Nacional de la Sociedad de Lucha 
Contra el Cáncer (ION SOLCA Matriz), in Guayaquil, 
Ecuador, which is responsible for the care of 50% to 70% 
of all cancers, in the country. The data obtained will provide 
guidance for prevention strategies, mainly of vaccination.
MATERIALS AND METHODS
Clinical samples
From January to December 2018 a cross sectional study 
was carried out in the Instituto Oncologico Nacional de 
la Sociedad de Lucha Contra el Cancer, in Guayaquil, 
Ecuador. During this period, a total of 800 genital brushings 
were obtained according to medical indication, from 
400 men and 400 women aged 10-70 years old. Samples 
were consecutively enrolled in the study. Genital samples 
were collected by using the Hybribio® PCR Cell Collection 
Media at the outpatient service SOLCA, from January 2015 
until December 2018. The collected samples were finally 
processed at SOLCA’s Molecular Biology Laboratory, 
which is a reference laboratory in the city.
DNA extraction
DNA extraction was performed following the 
methodology recommended by the manufacturer. 
HPV genotyping
HPV genotypes were identified using the 37 HPV 
GenoArray Diagnostic Kit (Hybribio® Diagnostics Ltd., 
Sheung Wan, Hong Kong) that identify the following 37 
HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 
56, 58, 59, 66, 68, 26, 34, 40, 54, 55, 57, 61, 67, 69, 70, 
71, 72, 73, 82, 83, 84, 6, 11, 42, 43, 44 and 81 (CP8304). 
Following the protocol provided by the manufacturer, a 
conventional PCR using the PGMY set of primers was 
performed (Applied Biosystems®/Gene Amp® 9700 thermal 
cycler). Immediately after amplification, the PCR product 
was denatured and hybridized through specific probes 
for 20 min. Additional steps included an initial washing, 
aggregation of the conjugate, blocking of the hybridization, 
secondary washing procedures and the addition of the 
substrate. This last step triggers the appearance of a specific 
spot thanks to a color reaction that occurs in the presence 
of the corresponding HPV genotype. 
The quality and the sufficiency of DNA samples for 
the PCR assays were evaluated by amplifying an internal 
control, that was included in the PCR mix. The absence of 
the internal control amplification constituted the samples 
exclusion criterium, even though the internal control of 
the dot blot had worked. This control was present in all 
the routines. 
Data analysis 
Results were considered positive if specific dot blots for 
any investigated HPV genotype and the internal control were 
present. The frequency and distribution of HPV genotypes 
was determined. HPV frequency according to sample 
characteristics (sex and age groups), was compared using 
c2 test. There was no need to obtain the informed consent 
from participants as the data were retrieved from daily HPV 
genotyping routines. This study was not evaluated by ethics 
committees due to the hospital’s internal policies. 
RESULTS
From the total of 800 samples (400 from men and 400 
from women), 411 were positive for HPV with an overall 
frequency of 51.38%. The frequency for men samples 
(253/400 or 63.25%) was higher than that of women 
samples (158/400 or 39.50%), with a p value <0.05. 
Comparing other characteristics, such as the detection of 
one or multiple HPV genotypes according to sex, or the 
frequency of HPV genotypes in different age groups, was 
not statistically significant with p values >0.05 (Table 1).
The most common viral genotype including both, men 
and women samples, was HPV 6, with 110 cases (relative 
frequency of 26.76%), followed by HPV 16, with 67 cases 
(relative frequency of 16.30%), HPV 39 with 43 cases 
(relative frequency of 10.46%) and HPV 11 with 35 cases 
(relative frequency of 8.52%). HPV 18 and HPV 58 were 
the following genotypes with 33 and 31 cases, respectively. 
Genotypes detected in women samples were: HPV 39 
(17.09%), HPV 16 (13.92%), HPV 6 (13.29%) and HPV 58 
(10.76%). Genotypes detected in men samples were: 
HPV 6 (35.18%), HPV 16 (17.39%), HPV 18 (10.67%) and 
HPV 11 (10.28%) (Figure 1). Overall, genotype 66, ranked 
seventh in frequency. Among female samples, this genotype 
exhibited a slightly higher frequency (8.86% vs 5.93%) 
(Figure 1). From the 411 positive samples, in 168 multiple 
genotypes were detected: 93 had two genotypes, 39 had 
three genotypes and 36 had more than three genotypes. 
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CONCLUSION
Human papillomavirus infection is one of the most 
prevalent viral sexually transmitted disease17. Approximately 
291 million women are harboring HPV viruses at any time 
in life, with 23% of these infections related to HPV 16 
and 8.5% to HPV 1818. The adjusted global prevalence has 
been reported as 10.41%, with regional differences in the 
frequency of carcinogenic HPV infections1. In the case 
of heterosexually identified men, an overall prevalence of 
50.5% was reported in the Study on Human Papillomavirus 
Infection in Men, that included participants from Brazil, 
Mexico and the United States19. Worldwide, 570.000 cancer 
cases per year in women and 60.000 cancer cases in men 
are attributable to HPV, representing 8.6% and 0.8% of 
all cancer cases. In the particular case of cervical cancer, 
infection rates standardized according to age that are over 
30 per 100.000 are reported mainly in sub-Saharan Africa 
and some places in Latin America and Oceania20.
To our knowledge, HPV has not been studied in both 
men and women in the city of Guayaquil, Ecuador. Most 
of the samples were sent to the laboratory with little or no 
information on the participants’ clinical conditions, previous 
diagnosis or treatment, besides gender and age. This lack 
of information was the main limitation of the study. The 
HPV frequency found in women samples (39.50%) and 
reported here were similar to the one from a previous 
observational study, using similar methodology but with a 
larger sample size of 1,581 Ecuadorian women (43.58%). 
We noticed, however, that some HPV genotypes associated 
Table 1 - Frequency of HPV-positive or –negative samples 
according to sex, age group and presence of one HPV genotype 
or multiple genotypes. 
Variables HPV+ HPV– p value c2 test
Sex
Men 253 147 < 0.05*
Women 158 242
Age (years)
18-29 144 120 >0.05
30-39 131 153
40-49 83 73
50-59 34 34
60-70 19 9  
Variables One genotype
Multiple 
genotypes
p value 
c2 test
Sex
Men 157 96 >0.05
Women 86 72
*Statistically significant
Figure 1 - Frequency of different human papillomavirus 
genotypes in men (depicted in black) and in women (depicted 
in white). 
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with cancer, including HPV 39 and HPV 58, appeared to 
be more frequent according to the locality21. A Peruvian 
study has also indicated an analogous frequency of HPV 
infection (43.4%), in a group of female college students22. 
On the contrary, a Colombian study reported a slightly 
higher frequency of HPV infection in female adolescents 
(48.97%)23. In the case of men, the frequency reported in 
this study (63.25%) was higher than the one reported for 
heterosexual men (50%)24. Furthermore, we observed that 
male samples showed a higher proportion of infection by 
HPV genotypes covered by currently used vaccines. This 
finding supports the need of to include men in vaccination 
strategies. As mentioned by other authors, only bivalent and 
tetravalent vaccines have been available for vaccination in 
Ecuador25-27. Due to the circulation of genotypes different 
from the ones covered by the available vaccines, a broader 
immunization strategy should be considered.
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